Reuters logo
EU agency backs Novo's new insulin, Lilly imaging agent
October 19, 2012 / 11:56 AM / 5 years ago

EU agency backs Novo's new insulin, Lilly imaging agent

LONDON, Oct 19 (Reuters) - Novo Nordisk’s ultra long-lasting insulin Tresiba has been recommended for approval for the European Medicines Agency in an important boost for the Danish drugmaker’s key new product.

The European endorsement, announced by the London-based agency on Friday, comes after the treatment hit regulatory delays in the United States.

Tresiba, or degludec, is central to Novo’s aim of ending Sanofi’s dominance of the long-acting insulin market.

The regulator also recommended a new Alzheimer’s imaging agent from Eli Lilly, the first radiopharmaceutical for PET imaging of beta-amyloid plaques, which are found in the brains of patients with the disease.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below